Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
ARDS 및 COVID-19 환자에서 덱사메타손의 효과 – 전향적, 다기관, 공개 라벨, 병렬 그룹, 무작위 대조 시험(REMED 시험): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] (C-reactive protein
24 hour
24 hours
administration
adrenal gland
Adult patients
Adverse
adverse events
age
alcohol
allergy
allocation
Antigen
ARDS
ARDS patients
ARMS
assumed
Barthel Index
benzyl alcohol
Berlin
Berlin criteria
Blinding
Block randomisation
Brazil
Breastfeeding
C-reactive protein
calculated
can be used
Cardiac arrest
Care
carried
case report form
CCI
Charlson Comorbidity Index
Chemotherapy
clinical
Comorbidity
comparator
completion
condition
conducted
consequence
Contraception
control group
Corticosteroid
Corticosteroids
COVID-19
COVID-19 ARDS patient
criteria
CRP
current
Czech Republic
Day
decision
defined
detect
Dexamethasone
dexamethasone 6 mg
diagnosed
dissemination
dose
doses
Dynamics
eCRF
Effect
Effectiveness
Efficacy and safety
electronic case report form
element
eligible
Endpoint
enrolled
enrolment
EudraCT
evaluate
event
expected
exploratory
Factor
followed by
French
gastrointestinal bleeding
HFNC
hospital
hospital discharge
Hospital stay
hypersensitivity
Hypothesis
ICU
ICU admission
ICUs
Identifier
Immunosuppression
immunosuppressive drug
immunosuppressive drugs
Independence
independent
independent of
Infection
infections
Inflammatory
infusion
intensive care unit
intensive care units
Intervention
intervention group
intractable
intravenously
intubate
intubation
investigational medicinal product
investigator
investigators
Laboratory
life
malignancy
marker
mechanical ventilation
medical history
moderate
moderate to severe
Mortality
nasal
nasal cannula
number
objective
observational study
once daily
Open-label
open-label trial
outcome
oxygen
Oxygen therapy
PaO
parallel-group
participant
Participation
Patient
patients with ARDS
patients with moderate
performed
power
power of 80%
Pragmatic
Pregnancy
present
primary efficacy endpoint
primary endpoint
protocol
Quality of life
randomisation
randomised
randomised controlled trial
receive
recruitment
Registered
routine clinical practice
RT-PCR
Sample size
scale
secondary
Secondary endpoints
Septic shock
sequence
severe ARDS
sexual abstinence
solution
Standard deviation
statistical analysis
statistician
status
Stratification
stratified
Study protocol
superinfection
supplementary material
systemic
systemic corticosteroids
thrombotic
Thrombotic complications
title
Treatment
treatment arm
Trial
Trial registration
two-sided
type I
type I error
university hospital
Ventilation
ventilator-free day
Ventilator-free days
Version
VFD
website
WHO
[DOI] 10.1186/s13063-021-05116-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05116-9 PMC 바로가기 [Article Type] Letter